Investors purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Monday. $249.51 million flowed into the stock on the tick-up and $75.04 million flowed out of the stock on the tick-down, for a money net flow of $174.47 million into the stock. Of all equities tracked, Pfizer had the highest net in-flow for the day. Pfizer traded down ($0.16) for the day and closed at $36.61
Several analysts have issued reports on the stock. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reiterated a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Morgan Stanley increased their target price on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. UBS Group set a $42.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average price target of $39.40.
The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The company has a market cap of $217,930.00, a price-to-earnings ratio of 20.92, a P/E/G ratio of 2.07 and a beta of 0.91.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same quarter last year, the firm earned $0.47 EPS. The firm’s quarterly revenue was up .6% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.71%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 77.71%.
Pfizer declared that its board has approved a stock buyback plan on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board believes its shares are undervalued.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 115,765 shares of company stock worth $4,217,653. 0.06% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in PFE. BlackRock Inc. lifted its position in shares of Pfizer by 2.8% in the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after purchasing an additional 12,183,218 shares during the period. Mackenzie Financial Corp lifted its position in shares of Pfizer by 29,164.7% in the 4th quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after purchasing an additional 11,442,753 shares during the period. Janus Henderson Group PLC lifted its position in shares of Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares during the period. Vanguard Group Inc. lifted its position in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares during the period. Finally, Amundi Pioneer Asset Management Inc. lifted its position in shares of Pfizer by 81.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock worth $691,583,000 after purchasing an additional 8,563,358 shares during the period. 71.41% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Investors Buy Pfizer (PFE) on Weakness” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/12/investors-buy-pfizer-pfe-on-weakness.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.